Long-term mortality in ICU patients with hematological malignancies: Impact of organ support duration and ICU length of stay
Authors' conclusion
One-year mortality among patients with hematological malignancy compared to matched controls was higher at the first day of admission and stayed higher for patients who remained in the ICU.
Study context
- Population
- ICU patients with hematological malignancies and matched non-hematological ICU patients
- Exposure
- Hematological malignancy vs matched non-hematological ICU controls
- Hematological malignancyn = 555
- Matched controlsn = 2.220reference
- Outcome
- Mortality by ICU LOS and organ support duration (landmark analyses)
- Follow-up
- 1 year following ICU admission
Methodological detailsmulticentre, matched (1:4, APACHE IV score and year of admission), landmark analyses
- Multicentre
- Matched (1:4, APACHE IV score and year of admission)
- Landmark analyses
Main finding
As reported in the abstract
ICU LOS ≥1 day: Hematological malignancy vs Matched controls
64 % vs 43 %
ICU LOS ≥7 days: Hematological malignancy vs Matched controls
72 % vs 42 %
ICU LOS ≥14 days: Hematological malignancy vs Matched controls
74 % vs 34 %
Observational data: associations, not effects.
Further findings
1-year mortality by RRT duration (1, 7, 14 days)
- RRT 1 day: Hematological malignancy vs Matched controls
- 79 % vs 60 %
- RRT 7 days: Hematological malignancy vs Matched controls
- 79 % vs 52 %
- RRT 14 days: Hematological malignancy vs Matched controls
- 85 % vs 55 %
1-year mortality by blood transfusion duration (1, 7, 14 days)
- Transfusion 1 day: Hematological malignancy vs Matched controls
- 74 % vs 47 %
- Transfusion 7 days: Hematological malignancy vs Matched controls
- 81 % vs 51 %
- Transfusion 14 days: Hematological malignancy vs Matched controls
- 86 % vs 50 %
1-year mortality by triple organ support duration (1, 7, 14 days)
- Triple organ support 1 day: Hematological malignancy vs Matched controls
- 84 % vs 54 %
- Triple organ support 7 days: Hematological malignancy vs Matched controls
- 84 % vs 51 %
- Triple organ support 14 days: Hematological malignancy vs Matched controls
- 94 % vs 56 %
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →